Fertility warning
This medicine may affect fertility.
Leaflet GEVESLA 150mg soft capsules
- Product code:
- W70878002
- Quantity:
- 60
- Indicated for:
- cancer
- Route of administration:
- oral
- Substance:
- nintedanib (antineoplastic agent)
- ATC
- L01EX09 — Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Nintedanib is a medication used for the treatment of idiopathic pulmonary fibrosis and other progressive interstitial lung diseases. It is a tyrosine kinase inhibitor that works by reducing inflammation and fibrosis in the lungs.
The medication is taken orally, usually twice daily with meals. The dose is adjusted based on the patient's tolerance and any adverse reactions. Common side effects include diarrhea, nausea, vomiting, and decreased appetite.
Nintedanib is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe liver impairment.
This medication is an important option for patients with progressive lung diseases, helping to slow disease progression and improve their quality of life.
The medication is taken orally, usually twice daily with meals. The dose is adjusted based on the patient's tolerance and any adverse reactions. Common side effects include diarrhea, nausea, vomiting, and decreased appetite.
Nintedanib is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe liver impairment.
This medication is an important option for patients with progressive lung diseases, helping to slow disease progression and improve their quality of life.
General data about GEVESLA 150mg
- Substance:
- nintedanib
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W70878002
- Concentration:
- 150mg
- Pharmaceutical form:
- soft capsules
- Quantity:
- 60
- Product type:
- Generic medicine
- Price:
- 6727.15 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for nintedanib
- 100mg
- 150mg
- 25mg
Compensation lists for GEVESLA 150mg Sanpha
NHP 6.20 (C2) - Idiopathic pulmonary fibrosis
- Price
- 6727.15 RON
- Copayment
- 4257.24 RON
- Patient
- 2469.91 RON